All Projects (70)

Multitargets drug for Sepsis: Mechanistic studies of drug action through mitigating infection and inflammatory responses associated with sepsis. Oct 1, 2023 - Sep 30, 2025
Sepsis is a life-threatening clinical condition caused by an overreacting immune system fighting an infection. It is often treated with broad-spectrum antibiotics together with anti-inflammatory drugs. However, due to the heterogeneous nature of the... Read More about Multitargets drug for Sepsis: Mechanistic studies of drug action through mitigating infection and inflammatory responses associated with sepsis..

Unlocking the biotechnological potential of Desertfilium tharense Aug 1, 2023 - Jul 31, 2024
Cyanobacteria, often known as blue-green algae, are an essential component of global ecosystems using light and carbon dioxide to produce organic carbon and oxygen. Consequently, they are found in diverse habitats including terrestrial and aquatic ha... Read More about Unlocking the biotechnological potential of Desertfilium tharense.

One Health Prescribing – New Analytical Methods to Inform Formulary Changes to Chiral Pharmaceuticals for Environmentally Friendlier Medicines Oct 1, 2023 - Sep 30, 2027
There is a need to reduce pollutants at source instead of relying on water treatment for their removal. The One Health Breakthrough Partnership is working to reduce pharmaceutical pollution entering the environment. This includes prescribing medicine... Read More about One Health Prescribing – New Analytical Methods to Inform Formulary Changes to Chiral Pharmaceuticals for Environmentally Friendlier Medicines.

Synthesis of substituted triazines and their investigation as corrosion inhibitors on mild steel and aluminium in corrosive environments Aug 1, 2023 - Dec 1, 2023
The serious consequences of the corrosion process have become a problem of worldwide significance - corrosion is the destructive attack of a material by reacting to its environment. Corrosion causes plant shutdowns, wastes valuable resources, causes... Read More about Synthesis of substituted triazines and their investigation as corrosion inhibitors on mild steel and aluminium in corrosive environments.

Exploring the anti-atherogenic properties of a compound derived from Amaryllidaceae (Daffodil) Sep 1, 2023 - Apr 30, 2024
Agroceutical Products Ltd (APL) produces sustainable quantities of the naturally derived alkaloid galanthamine from daffodils, which is a key active pharmaceutical used for the treatment of Alzheimer’s disease. Daffodils contain an abundance of other... Read More about Exploring the anti-atherogenic properties of a compound derived from Amaryllidaceae (Daffodil).

Bioactivity of a compound derived from Amaryllidaceae (Daffodil) in a C.elegans model of obesity Sep 1, 2023 - Apr 30, 2024
A previous proof-of-concept study demonstrated that an alkaloid extracted from daffodil bulbs by Agroceutical Products Ltd (APL), alongside sustainable galanthamine production (alkaloid used for Alzheimer’s disease management), selectively reduced re... Read More about Bioactivity of a compound derived from Amaryllidaceae (Daffodil) in a C.elegans model of obesity.

Yes/No shellfish toxin test Sep 1, 2023 - Mar 31, 2024
The UK shellfish industry uses qualitative tests for management of range of toxins in shellfish products. The only supplier of these tests, Neogen will discontinue these tests by the end of 2023. CyanSol group and partners are dedicated to developin... Read More about Yes/No shellfish toxin test.

One Health Medicine – developing a predictive tool for pharmaceuticals in wastewater Oct 30, 2023 - Nov 1, 2024
Medicines are used everyday by humans. However, they can be detrimental to aquatic life. Pharmaceuticals enter the environment following human excretion and transport through wastewater systems. The danger pharmaceuticals pose is location specific de... Read More about One Health Medicine – developing a predictive tool for pharmaceuticals in wastewater.

How do fresh whole blood and blood component therapies containing additive solutions alter the structure and stability of a blood clot during traumatic bleeding? Dec 1, 2023 - Nov 30, 2024
In a military setting, bleeding is the primary cause of preventable death in patients suffering from polytrauma and massive haemorrhage. Access to hospital care and blood products is limited by location, logistics and personnel. Pre-hospital blood in... Read More about How do fresh whole blood and blood component therapies containing additive solutions alter the structure and stability of a blood clot during traumatic bleeding?.

Binding affinity of different commercial FIX therapies to collagen IV Oct 1, 2023 - Sep 30, 2024
Haemophilia B is a blood clotting disorder caused by deficiency of blood coagulation Factor IX (FIX), resulting in bruising and bleeding. Haemophilia B affects 1:30,000 males in the UK and is treated by infusion of FIX concentrate to sustain normal f... Read More about Binding affinity of different commercial FIX therapies to collagen IV.